{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T06:11:24Z","timestamp":1777011084494,"version":"3.51.4"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T00:00:00Z","timestamp":1701993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T00:00:00Z","timestamp":1701993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Metastasis"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s10585-023-10241-7","type":"journal-article","created":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T11:02:45Z","timestamp":1702033365000},"page":"439-445","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Management of melanoma: can we use gene expression profiling to help guide treatment and surveillance?"],"prefix":"10.1007","volume":"41","author":[{"given":"Jonathan S.","family":"Zager","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Hyams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,8]]},"reference":[{"key":"10241_CR1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21731","author":"KD Miller","year":"2022","unstructured":"Miller KD et al (2022) Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin. https:\/\/doi.org\/10.3322\/caac.21731","journal-title":"CA Cancer J Clin"},{"key":"10241_CR2","doi-asserted-by":"publisher","first-page":"731","DOI":"10.2105\/AJPH.2020.305567","volume":"110","author":"J Berk-Krauss","year":"2020","unstructured":"Berk-Krauss J, Stein JA, Weber J, Polsky D, Geller AC (2020) New systematic therapies and trends in cutaneous melanoma deaths among US Whites, 1986\u20132016. Am J Public Health 110:731\u2013733","journal-title":"Am J Public Health"},{"key":"10241_CR3","unstructured":"NCCN Clinical Practice Guidelines in Oncology: Melanoma: Cutaneous Version 1.2023. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cutaneous_melanoma.pdf"},{"key":"10241_CR4","unstructured":"Gershenwald JE et al (2017) AJCC cancer staging manual. In: 8th edition AJCC melanoma staging system. Springer, New York, pp 563\u2013589"},{"key":"10241_CR5","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3322\/caac.21409","volume":"67","author":"JE Gershenwald","year":"2017","unstructured":"Gershenwald JE et al (2017) Melanoma staging: evidence-based changes in the American Joint Committee on cancer eighth edition staging manual. CA Cancer J Clin 67:472\u2013492","journal-title":"CA Cancer J Clin"},{"key":"10241_CR6","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1245\/s10434-018-6513-7","volume":"25","author":"JE Gershenwald","year":"2018","unstructured":"Gershenwald JE, Scolyer RA (2018) Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th edition and Beyond. Ann Surg Oncol 25:2105\u20132110","journal-title":"Ann Surg Oncol"},{"key":"10241_CR7","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1002\/ijc.32930","volume":"147","author":"PD Baade","year":"2020","unstructured":"Baade PD et al (2020) Long-term deaths from melanoma according to tumor thickness at diagnosis. Int J Cancer 147:1391\u20131396","journal-title":"Int J Cancer"},{"key":"10241_CR8","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa1310460","volume":"370","author":"DL Morton","year":"2014","unstructured":"Morton DL et al (2014) Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med 370:599\u2013609","journal-title":"N Engl J Med"},{"key":"10241_CR9","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1245\/s10434-017-6267-7","volume":"25","author":"SL Wong","year":"2018","unstructured":"Wong SL et al (2018) Sentinel lymph node biopsy and management of regional lymph nodes in melanoma: American Society of Clinical Oncology and Society of Surgical Oncology clinical practice guideline update. Ann Surg Oncol 25:356\u2013377","journal-title":"Ann Surg Oncol"},{"key":"10241_CR10","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1002\/cncr.29239","volume":"121","author":"M Yamamoto","year":"2015","unstructured":"Yamamoto M et al (2015) Sentinel lymph node biopsy is indicated for patients with thick clinically lymph node-negative melanoma. Cancer 121:1628\u20131636","journal-title":"Cancer"},{"key":"10241_CR11","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.ejso.2016.06.407","volume":"43","author":"JA Moody","year":"2017","unstructured":"Moody JA, Ali RF, Carbone AC, Singh S, Hardwicke JT (2017) Complications of sentinel lymph node biopsy for melanoma\u2014a systematic review of the literature. Eur J Surg Oncol 43:270\u2013277","journal-title":"Eur J Surg Oncol"},{"key":"10241_CR12","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1245\/s10434-012-2469-1","volume":"19","author":"D Han","year":"2012","unstructured":"Han D et al (2012) Sentinel node biopsy is indicated for thin melanomas \u2265 0.76 mm. Ann Surg Oncol 19:3335\u20133342","journal-title":"Ann Surg Oncol"},{"key":"10241_CR13","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.1200\/JCO.2013.50.1114","volume":"31","author":"D Han","year":"2013","unstructured":"Han D et al (2013) Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma. J Clin Oncol 31:4387\u20134393","journal-title":"J Clin Oncol"},{"key":"10241_CR14","doi-asserted-by":"publisher","unstructured":"Multicenter Selective Lymphadenectomy Trials Study Group et al (2022) Therapeutic value of sentinel lymph node biopsy in patients with melanoma: a randomized clinical trial. JAMA Surg. https:\/\/doi.org\/10.1001\/jamasurg.2022.2055","DOI":"10.1001\/jamasurg.2022.2055"},{"key":"10241_CR15","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","volume":"376","author":"MB Faries","year":"2017","unstructured":"Faries MB et al (2017) Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med 376:2211\u20132222","journal-title":"N Engl J Med"},{"key":"10241_CR16","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.jamcollsurg.2020.11.014","volume":"232","author":"KK Broman","year":"2021","unstructured":"Broman KK et al (2021) Surveillance of sentinel node-positive melanoma patients with reasons for exclusion from MSLT-II: multi-institutional propensity score matched analysis. J Am Coll Surg 232:424\u2013431","journal-title":"J Am Coll Surg"},{"key":"10241_CR17","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1002\/cncr.33483","volume":"127","author":"KK Broman","year":"2021","unstructured":"Broman KK et al (2021) Active surveillance of patients who have sentinel node positive melanoma: an international, multi-institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT-2). Cancer 127:2251\u20132261","journal-title":"Cancer"},{"key":"10241_CR18","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1056\/NEJMra2034861","volume":"384","author":"BD Curti","year":"2021","unstructured":"Curti BD, Faries MB (2021) Recent advances in the treatment of melanoma. N Engl J Med 384:2229\u20132240","journal-title":"N Engl J Med"},{"key":"10241_CR19","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa2005493","volume":"383","author":"R Dummer","year":"2020","unstructured":"Dummer R et al (2020) Five-year analysis of adjuvant Dabrafenib plus Trametinib in stage III melanoma. N Engl J Med 383:1139\u20131148","journal-title":"N Engl J Med"},{"key":"10241_CR20","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1200\/JCO.20.02110","volume":"38","author":"AMM Eggermont","year":"2020","unstructured":"Eggermont AMM et al (2020) Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: updated results from the EORTC 1325-MG\/KEYNOTE-054 trial. JCO 38:3925\u20133936","journal-title":"JCO"},{"key":"10241_CR21","doi-asserted-by":"publisher","first-page":"LBA9505","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA9505","volume":"41","author":"JJ Luke","year":"2023","unstructured":"Luke JJ et al (2023) Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study. JCO 41:LBA9505","journal-title":"JCO"},{"key":"10241_CR22","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","volume":"399","author":"JJ Luke","year":"2022","unstructured":"Luke JJ et al (2022) Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. The Lancet 399:1718\u20131729","journal-title":"The Lancet"},{"key":"10241_CR23","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/S1470-2045(21)00065-6","volume":"22","author":"AMM Eggermont","year":"2021","unstructured":"Eggermont AMM et al (2021) Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncol 22:643\u2013654","journal-title":"Lancet Oncol"},{"key":"10241_CR24","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.3390\/cancers12071994","volume":"12","author":"AAE Testori","year":"2020","unstructured":"Testori AAE, Chiellino S, van Akkooi ACJ (2020) Adjuvant therapy for melanoma: past, current, and future developments. Cancers 12:1994","journal-title":"Cancers"},{"key":"10241_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-023-00775-7","author":"E Chatziioannou","year":"2023","unstructured":"Chatziioannou E et al (2023) Features and long-term outcomes of stage IV melanoma patients achieving complete response under anti-PD-1-based immunotherapy. Am J Clin Dermatol. https:\/\/doi.org\/10.1007\/s40257-023-00775-7","journal-title":"Am J Clin Dermatol"},{"issue":"23","key":"10241_CR26","doi-asserted-by":"publisher","first-page":"00734","DOI":"10.1016\/j.annonc.2023.06.006","volume":"S0923\u20137534","author":"CE Sharon","year":"2023","unstructured":"Sharon CE et al (2023) Long-term outcomes to neoadjuvant pembrolizumab based on pathological response for patients with resectable stage III\/IV cutaneous melanoma. Ann Oncol S0923\u20137534(23):00734\u201300742. https:\/\/doi.org\/10.1016\/j.annonc.2023.06.006","journal-title":"Ann Oncol"},{"key":"10241_CR27","first-page":"e90","volume":"32","author":"A Poklepovic","year":"2018","unstructured":"Poklepovic A, Carvajal R (2018) Prognostic value of low tumor burden in patients with melanoma. Oncology 32:e90\u2013e96","journal-title":"Oncology"},{"key":"10241_CR28","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41467-022-27960-2","volume":"13","author":"M Conroy","year":"2022","unstructured":"Conroy M, Naidoo J (2022) Immune-related adverse events and the balancing act of immunotherapy. Nat Commun 13:392","journal-title":"Nat Commun"},{"key":"10241_CR29","doi-asserted-by":"publisher","first-page":"1143354","DOI":"10.3389\/fonc.2023.1143354","volume":"13","author":"MV Papageorge","year":"2023","unstructured":"Papageorge MV et al (2023) The role of imaging and sentinel lymph node biopsy in patients with T3b\u2013T4b melanoma with clinically negative disease. Front Oncol 13:1143354","journal-title":"Front Oncol"},{"key":"10241_CR30","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1002\/cncr.21189","volume":"104","author":"JD Wagner","year":"2005","unstructured":"Wagner JD et al (2005) Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma. Cancer 104:570\u2013579","journal-title":"Cancer"},{"key":"10241_CR31","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1245\/s10434-022-13034-6","volume":"30","author":"NM Helvind","year":"2023","unstructured":"Helvind NM et al (2023) Earlier recurrence detection using routine FDG PET-CT scans in surveillance of stage IIB to IIID melanoma: a national cohort study of 1480 patients. Ann Surg Oncol 30:2377\u20132388","journal-title":"Ann Surg Oncol"},{"key":"10241_CR32","doi-asserted-by":"publisher","DOI":"10.5603\/NMR.a2022.0039","author":"Z Dancheva","year":"2022","unstructured":"Dancheva Z et al (2022) Diagnostic and clinical value of [18F]FDG PET\/CT in the follow-up regimen in IIA-IIID stage cutaneous malignant melanoma after first regional recurrence. Nucl Med Rev Cent East Eur. https:\/\/doi.org\/10.5603\/NMR.a2022.0039","journal-title":"Nucl Med Rev Cent East Eur"},{"key":"10241_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00801-2","author":"PR Cohen","year":"2022","unstructured":"Cohen PR, Kurzrock R (2022) Dermatologic Disease-Directed Targeted Therapy (D3T2): the application of biomarker-based precision medicine for the personalized treatment of skin conditions-precision dermatology. Dermatol Ther. https:\/\/doi.org\/10.1007\/s13555-022-00801-2","journal-title":"Dermatol Ther"},{"key":"10241_CR34","unstructured":"National Comprehensive Cancer Network. (2023) Breast Cancer, Version 4.2023. Breast Cancer, Version 4.2023. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf"},{"key":"10241_CR35","unstructured":"National Comprehensive Cancer Network: Melanoma: Uveal, NCCN Guidelines Version 1.2022, in NCCN Clinical Practice Guidelines in Oncology. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/uveal.pdf"},{"key":"10241_CR36","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1158\/1078-0432.CCR-13-3316","volume":"21","author":"P Gerami","year":"2015","unstructured":"Gerami P et al (2015) Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma. Clin Cancer Res 21:175\u2013183","journal-title":"Clin Cancer Res"},{"key":"10241_CR37","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.jaad.2020.03.053","volume":"83","author":"BN Greenhaw","year":"2020","unstructured":"Greenhaw BN et al (2020) Molecular risk prediction in cutaneous melanoma: a meta-analysis of the 31-gene expression profile prognostic test in 1479 patients. J Am Acad Dermatol 83:745\u2013753","journal-title":"J Am Acad Dermatol"},{"key":"10241_CR38","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1200\/PO.20.00119","volume":"5","author":"EC Hsueh","year":"2021","unstructured":"Hsueh EC et al (2021) Long-term outcomes in a multicenter, prospective cohort evaluating the prognostic 31-gene expression profile for cutaneous melanoma. JCO Precis Oncol 5:589\u2013601","journal-title":"JCO Precis Oncol"},{"key":"10241_CR39","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/j.amjsurg.2021.03.028","volume":"221","author":"SP Arnot","year":"2021","unstructured":"Arnot SP et al (2021) Utility of a 31-gene expression profile for predicting outcomes in patients with primary cutaneous melanoma referred for sentinel node biopsy. Am J Surg 221:1195\u20131199","journal-title":"Am J Surg"},{"key":"10241_CR40","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s12885-018-4016-3","volume":"18","author":"JS Zager","year":"2018","unstructured":"Zager JS et al (2018) Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients. BMC Cancer 18:130","journal-title":"BMC Cancer"},{"key":"10241_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.10.062","author":"RB Thorpe","year":"2021","unstructured":"Thorpe RB et al (2021) Development and validation of a nomogram incorporating gene expression profiling and clinical factors for accurate prediction of metastasis in patients with cutaneous melanoma following Mohs micrographic surgery. J Am Acad Dermatol. https:\/\/doi.org\/10.1016\/j.jaad.2021.10.062","journal-title":"J Am Acad Dermatol"},{"key":"10241_CR42","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1002\/cam4.2128","volume":"8","author":"J Keller","year":"2019","unstructured":"Keller J et al (2019) Prospective validation of the prognostic 31-gene expression profiling test in primary cutaneous melanoma. Cancer Med 8:2205\u20132212","journal-title":"Cancer Med"},{"key":"10241_CR43","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1097\/DSS.0000000000001588","volume":"44","author":"BN Greenhaw","year":"2018","unstructured":"Greenhaw BN, Zitelli JA, Brodland DG (2018) Estimation of prognosis in invasive cutaneous melanoma: an independent study of the accuracy of a gene expression profile test. Dermatol Surg 44:1494\u20131500","journal-title":"Dermatol Surg"},{"key":"10241_CR44","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1080\/03007995.2022.2033560","volume":"38","author":"LD Dillon","year":"2022","unstructured":"Dillon LD et al (2022) Expanded evidence that the 31-gene expression profile test provides clinical utility for melanoma management in a multicenter study. Curr Med Res Opin 38:1267\u20131274","journal-title":"Curr Med Res Opin"},{"key":"10241_CR45","doi-asserted-by":"publisher","DOI":"10.1177\/00031348221081760","author":"A Williams","year":"2022","unstructured":"Williams A, Hamilton O, Likar C, Thomay A, Garland-Kledzik M (2022) The benefit of positron emission tomography\/computed tomography in stage I and stage II melanomas with high-risk decisiondx-melanoma scores. Am Surg. https:\/\/doi.org\/10.1177\/00031348221081760","journal-title":"Am Surg"},{"key":"10241_CR46","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1177\/0003134820939944","volume":"86","author":"AM Scott","year":"2020","unstructured":"Scott AM, Dale PS, Conforti A, Gibbs JN (2020) Integration of a 31-gene expression profile into clinical decision-making in the treatment of cutaneous melanoma. Am Surg 86:1561\u20131564","journal-title":"Am Surg"},{"key":"10241_CR47","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.jamcollsurg.2018.12.030","volume":"228","author":"ME Egger","year":"2019","unstructured":"Egger ME et al (2019) Should sentinel lymph node biopsy be performed for all T1b melanomas in the new 8th edition American Joint Cancer Staging System? J Am Coll Surg 228:466\u2013472","journal-title":"J Am Coll Surg"},{"key":"10241_CR48","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.jaad.2018.08.022","volume":"80","author":"AN Hanna","year":"2019","unstructured":"Hanna AN et al (2019) Relationship between age and likelihood of lymph node metastases in patients with intermediate thickness melanoma (1.01\u20134.00 mm): a National Cancer Database study. J Am Acad Dermatol 80:433\u2013440","journal-title":"J Am Acad Dermatol"},{"key":"10241_CR49","doi-asserted-by":"publisher","first-page":"3955","DOI":"10.1245\/s10434-019-07690-4","volume":"26","author":"ME Egger","year":"2019","unstructured":"Egger ME et al (2019) Age and lymphovascular invasion accurately predict sentinel lymph node metastasis in T2 melanoma patients. Ann Surg Oncol 26:3955\u20133961","journal-title":"Ann Surg Oncol"},{"key":"10241_CR50","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.2217\/fon-2018-0912","volume":"15","author":"JT Vetto","year":"2019","unstructured":"Vetto JT et al (2019) Guidance of sentinel lymph node biopsy decisions in patients with T1\u2013T2 melanoma using gene expression profiling. Future Oncol 15:1207\u20131217","journal-title":"Future Oncol"},{"key":"10241_CR51","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.jaad.2018.07.028","volume":"80","author":"BR Gastman","year":"2019","unstructured":"Gastman BR et al (2019) Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria. J Am Acad Dermatol 80:149\u2013157","journal-title":"J Am Acad Dermatol"},{"key":"10241_CR52","doi-asserted-by":"publisher","DOI":"10.1200\/PO.21.00162","author":"ED Whitman","year":"2021","unstructured":"Whitman ED et al (2021) Integrating 31-gene expression profiling with clinicopathologic features to optimize cutaneous melanoma sentinel lymph node metastasis prediction. JCO Precis Oncol. https:\/\/doi.org\/10.1200\/PO.21.00162","journal-title":"JCO Precis Oncol"},{"key":"10241_CR53","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/j.jaad.2022.06.1202","volume":"87","author":"A Jarell","year":"2022","unstructured":"Jarell A et al (2022) Optimizing treatment approaches for patients with cutaneous melanoma by integrating clinical and pathologic features with the 31-gene expression profile test. J Am Acad Dermatol 87:1312\u20131320","journal-title":"J Am Acad Dermatol"},{"key":"10241_CR54","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1080\/03007995.2023.2165813","volume":"39","author":"M Yamamoto","year":"2023","unstructured":"Yamamoto M et al (2023) The 31-gene expression profile test informs sentinel lymph node biopsy decisions in patients with cutaneous melanoma: results of a prospective, multicenter study. Curr Med Res Opin 39:417\u2013423","journal-title":"Curr Med Res Opin"},{"key":"10241_CR55","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-023-02613-6","author":"S Dhillon","year":"2023","unstructured":"Dhillon S et al (2023) Routine imaging guided by a 31-gene expression profile assay results in earlier detection of melanoma with decreased metastatic tumor burden compared to patients without surveillance imaging studies. Arch Dermatol Res. https:\/\/doi.org\/10.1007\/s00403-023-02613-6","journal-title":"Arch Dermatol Res"},{"key":"10241_CR56","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.jaad.2015.01.009","volume":"72","author":"P Gerami","year":"2015","unstructured":"Gerami P et al (2015) Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy. J Am Acad Dermatol 72:780\u2013785","journal-title":"J Am Acad Dermatol"},{"key":"10241_CR57","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.3390\/cancers14041060","volume":"14","author":"S Podlipnik","year":"2022","unstructured":"Podlipnik S et al (2022) Using a 31-gene expression profile test to stratify patients with stage I-II cutaneous melanoma according to recurrence risk: update to a prospective, multicenter study. Cancers 14:1060","journal-title":"Cancers"},{"key":"10241_CR58","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/nature22079","volume":"545","author":"AC Huang","year":"2017","unstructured":"Huang AC et al (2017) T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 545:60\u201365","journal-title":"Nature"},{"key":"10241_CR59","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1001\/jama.2016.4059","volume":"315","author":"A Ribas","year":"2016","unstructured":"Ribas A et al (2016) Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 315:1600\u20131609","journal-title":"JAMA"}],"container-title":["Clinical & Experimental Metastasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-023-10241-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10585-023-10241-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-023-10241-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T15:13:23Z","timestamp":1725462803000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10585-023-10241-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,8]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10241"],"URL":"https:\/\/doi.org\/10.1007\/s10585-023-10241-7","relation":{},"ISSN":["0262-0898","1573-7276"],"issn-type":[{"value":"0262-0898","type":"print"},{"value":"1573-7276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,8]]},"assertion":[{"value":"17 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JSZ receives personal fees from Castle Biosciences, Inc, JSZ is a co-investigator for ongoing Skyline Dx clinical trial. DMH receives honoraria from and is a consultant and speaker for Exact Sciences and Castle Biosciences, Inc.  DMH receives research funding from Castle Biosciences, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}